NLRP3 and Opportunistic infection: Increased specificity afforded by directly blocking NLRP3 would not prevent activation of the other members of the NOD family, therefore, the risk of opportunist infection reported with anti-IL-1 biologics should be more limited with NLRP3 inhibitors.